Information Provided By: 
Fly News Breaks for June 14, 2016
RVNC
Jun 14, 2016 | 10:15 EDT
Cowen analyst Ken Cacciatore said he shares in the disappointment that Revance's RT001 program is not moving forward, but adds that he believes expectations were low and that investor focus had already shifted, and remains fixed, on the injectable RT002 program, which is the company's key value driver. Cacciatore, who still thinks that RT002 could become a $1B+ product, maintains an Outperform rating and $55 price target on Revance shares, which are down 22% to $14.30 in morning trading.
News For RVNC From the Last 2 Days
There are no results for your query RVNC
